Chemoradiation Boosts Survival in Patients With Nasopharynx Cancer
July 1st 1996ASCO--The preliminary results of an Intergroup study of patients with locally advanced nasopharyngeal cancer show a highly significant improvement in survival with the use of chemoradia-tion, compared with radiation alone, Muhyi Al-Sarraf, MD, said at the ASCO plenary session.
PCR-Based HIV Test Monitors Viral Load
July 1st 1996BRANCHBURG, NJ--Roche Diagnostic Systems Inc.'s Amplicor H.I.V.-1 monitor test for use in determining viral load in individuals infected with HIV has received FDA approval for marketing. The test uses polymerase chain reaction (PCR) technology to measure HIV genetic material in the blood.
NCI Acts as Catalyst for New Middle East Cancer Consortium
July 1st 1996BETHESDA, Md--The National Cancer Institute has orchestrated an agreement between the Ministers of Health of Cyprus, Egypt, Israel, Jordan, and the Palestinian Authority. The five ministers recently gathered in Geneva to sign the Middle East Cancer Consortium (MECC) agreement.
FDA Approves Camptosar for Metastatic Colorectal Cancer
July 1st 1996GAITHERSBURG, Md--By a unanimous vote, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended accelerated approval of Pharmacia & Upjohn's Camptosar (irinotecan hydrochloride injection), and the FDA responded by giving its ok to the drug 28 hours later.
Zosyn Is Cleared for Treatment Of Nosocomial Pneumonia
July 1st 1996ST. DAVIDS, Penn--Wyeth-Ayerst Laboratories' Zosyn (pipera-cillin/tazobactam) is now indicated for use in treating moderate to severe nosocomial pneumonia caused by piperacillin-resistant beta-lactamase-producing strains of Staphylococcus aureus. In a multicenter study of 300 patients with nosocomial pneumonia, the rate of clinical cure or improvement for Zosyn plus tobramycin was 74%, compared with 50% for cef-tazidime plus tobramycin, the company said.
University of Pittsburgh, Abbott Labs to Develop Ras Inhibitors
July 1st 1996PITTSBURGH--The University of Pittsburgh, through the researchof investigators Saïd Sebti, PhD, and Andrew Hamilton, PhD,has entered into a research agreement with Abbott Laboratoriesto develop novel cancer drugs that block the activity of the rasoncogene.
Defining the Role of Post-Mastectomy Radiotherapy: The New Evidence
July 1st 1996I will briefly comment on two points discussed by Pierce and Lichter in their thorough review: (1) the recently published Oxford overview analysis of locoregional therapies [1], and (2) which patients may benefit from postmastectomy radiotherapy.
Anorexia/Cachexia in Patients with HIV: Lessons for the Oncologist
July 1st 1996This article provides a nice overview of HIV-associated wasting. The paper makes a number of strong points. In particular, it focuses on anorexia and decreased oral intake as key to wasting. In this vein, both the discussion by Von Roenn and Knopf and Tables 1 and 2 offer a very valuable review of the multiple reasons why HIV-infected patients may eat less. Given the many medications that we often need to use in these patients, the text discussion about the ways in which medications can result in decreased oral intake, reinforced by Table 2, is particularly useful.
Insurance Policies for Cancer: Made in Japan
July 1st 1996The financial burden of a long-term illness such as cancer can be devastating, with as much as 66% of the costs of cancer being nonmedical[1]. These financial concerns are leading some Americans to buy insurance policies that, upon diagnosis of cancer, assist them in paying for their care.
Anorexia/Cachexia in Patients with HIV: Lessons for the Oncologist
July 1st 1996Von Roenn and Knopf provide a balanced review of the pathophysiology and treatment options for anorexia and cachexia associated with HIV and cancer. This is an important topic that cuts across subspecialty lines and typically frustrates clinicians. Fortunately, more has probably been learned about HIV-associated cachexia during the past decade than about cancer-associated cachexia during the previous three decades and a number of treatment options have emerged. The reader may therefore benefit from a summary of the practical implications of recent research on HIV-associated wasting. Several clinical guidelines can be recommended:
Combinations of Hormones and Local Therapies in Locally Advanced Prostate Carcinoma
July 1st 1996Eulau and Corn provide an excellent review of the current status of neoadjuvant androgen deprivation therapy combined with radiation therapy or surgery in the management of locally advanced prostatic cancer. They comprehensively describe the
Anorexia/Cachexia in Patients with HIV: Lessons for the Oncologist
July 1st 1996Early intervention and attention to nutritional status are essential in patients with cachexia. Identification of reversible causes of decreased energy intake and/or weight loss is the first step in treatment. When such factors
Patent Granted for MoAbs Used in Neoprobe's RIGScan Products
July 1st 1996DUBLIN, Ohio--Neoprobe Corporation has announced that a patent granted to Jeffrey Schlom, PhD, of the National Cancer Institute, and David Colcher, PhD, of the University of Nebraska Medical Center, covers claims to composition of matter for a large group of second-generation monoclonal antibodies that target the tumor-associated antigen TAG-72.
System Using Interactive Video Brings Oncology Services to Rural Kansans
July 1st 1996ASCO--After more than a year of operating a teleoncology service, University of Kansas researchers have seen no discrepancies between consultations conducted via interactive video and subsequent on-site assessments. The University turned to teleoncology to better serve patients in sparsely settled areas of the state, Gary C. Doolittle, MD, co-director of the telemedicine service, said in his ASCO presentation in Philadelphia.
Home Test for AIDS Virus Is Being Test Marketed in Two States
July 1st 1996NEW BRUNSWICK, NJ--Confide, the first home collection HIV testing and counseling service, has received FDA approval and is now being test marketed in Texas and Florida. The test was developed by Direct Access Diagnostics, a Johnson & Johnson subsidiary based in Bridgewater, NJ, in conjunction with Chiron Corporation.
AIDS Activists Issue Safeguards for People With AIDS Who Sell Their Life Insurance Policies
July 1st 1996With the goal of protecting the economic security of people with AIDS (PWAs) who decide to sell their life insurance policies to obtain cash, a group of leading advocates for PWAs met in Los Angeles on March 22 to draft a set of standards
AIDS-related Kaposi's Sarcoma: Options for Today and Tomorrow
June 2nd 1996Prior to 1981, Kaposi sarcoma (KS) was considered a rare human cancer occurring primarily among elderly Italian and Jewish men of eastern European ancestry. I wrote a review of KS research and clinical experiences that appeared in CA: A
Psychosocial Oncology May Benefit From System Reform
June 1st 1996PALM SPRINGS, Calif--The United Kingdom, not unlike the United States, is undergoing a period of radical change in the organization of cancer services, the status of the medical professionals delivering those services, and the climate for conducting clinical research, Ann Cull, PhD, said at the American Society for Psychiatric Oncology/AIDS meeting.
Know Your Partners, Know Your Goals in Joint Ventures Between Hospitals and Universities
June 1st 1996WASHINGTON--Joint ventures between community hospitals and university departments of oncology can offer significant benefits to both, but not unless all parties involved understand one another and formulate a well thought out program.
Managed Care Reform: Wait Until Next Year for House, Senate
June 1st 1996WASHINGTON--Despite increasing complaints from physicians and patients, don't look for Congress to take any action in 1996 to remedy the problems that have evolved with the growth of managed care, a key Senate aide said at the national meeting of the Association of Community Cancer Centers (ACCC).
Pain Scale Resembling Thermometer May Be Easier to Use Than VAS
June 1st 1996MONTREAL--A new instrument for measuring pain intensity--the visual analogue thermometer (VAT)--developed to overcome some of the disadvantages of the conventional visual analogue scale (VAS)--has proved "valid, accurate, and clinically useful" in two studies, say Manon Choinière, PhD, of the Burn Centre, Hotel-Dieu Hospital of Montreal and the University of Montreal, and Rhonda Amsel, MSc, of the Department of Psychology, McGill University.
Medicine as Business May Mean More Ethical Challenges for Physicians
June 1st 1996Physicians today are facing more ethical dilemmas as patient decisions are being based less on beneficence and more on business models of success, says Sister Patricia Talone, ethics consultant, Mercy Health Corporation of Southeastern